Literature DB >> 17393109

Effect of antisense oligodeoxynucleotide of vascular endothelial growth factor C on lymphangiogenesis and angiogenesis of pancreatic cancer.

Kai Li1, Jing Tao, Tao Li, Zhou Yu, Zhiyong Yang, Heshui Wu, Jiongxin Xiong, Chunyou Wang.   

Abstract

In order to investigate the effect of antisense oligonucleotide (ASODN) of vascular endothelial growth factor C (VEGF-C) on lymphangiogenesis and angiogenesis of pancreatic cancer, antisense and scamble-sense oligonucleotide of VEGF-C were constructed, and the model of nude mice with orthotopically xenografted human pancreatic cancer cells (Panc-1) was established. Thirty nude mice were randomly divided into 3 groups: PBS control group (group A), scramble-sense control group (group B) and antisense group (group C). All nude mice were treated once every 2 days as 3 times per week, for 3 weeks (oligonucleotide 10 mg/kg every time). After treatments were completed, ELISA method was used to examine the concentration of VEGF-C in plasma and immunohistochemical method to examine microvessel density (MVD), lymphtic vessel density (LVD) of pancreatic cancer. The results showed that the expression of VEGF-C was inhibited significantly in group C. The concentrations were 237.5+/-41.5, 221.5+/-52.3 and 108.6+/-14.9 pg/mL in groups A, B and C respectively (P<0.01). LVD in groups A, B and C was 13.8+/-2.1, 12.4+/-1.9 and 4.2+/-1.6 respectively (P<0.01). MVD in groups A, B and C was 27.5+/-8.7, 25.9+/-4.2 and 19.4+/-5.6 respectively with no significant difference among the groups (P>0.05). It was suggested that VEGF-C ASODN decreased the expression levels of VEGF-C in nude mice with orthotopically xenografted human pancreatic cancer, and it could inhibit lymphangiogenesis, but had no significant effect on angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17393109     DOI: 10.1007/s11596-007-0115-0

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

Review 1.  Liposome-mediated delivery of oligodeoxynucleotides in vivo.

Authors:  Crispin R Dass
Journal:  Drug Deliv       Date:  2002 Jul-Sep       Impact factor: 6.419

Review 2.  Intratumor microvessel density as a prognostic factor in cancer.

Authors:  N Weidner
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

3.  Proteolytic processing regulates receptor specificity and activity of VEGF-C.

Authors:  V Joukov; T Sorsa; V Kumar; M Jeltsch; L Claesson-Welsh; Y Cao; O Saksela; N Kalkkinen; K Alitalo
Journal:  EMBO J       Date:  1997-07-01       Impact factor: 11.598

4.  Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer.

Authors:  R F Tang; J Itakura; T Aikawa; K Matsuda; H Fujii; M Korc; Y Matsumoto
Journal:  Pancreas       Date:  2001-04       Impact factor: 3.327

5.  Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.

Authors:  M Skobe; L M Hamberg; T Hawighorst; M Schirner; G L Wolf; K Alitalo; M Detmar
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

6.  VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer.

Authors:  Hubert G Hotz; O Joe Hines; Rizwan Masood; Birgit Hotz; Thomas Foitzik; Heinz J Buhr; Parkash S Gill; Howard A Reber
Journal:  Surgery       Date:  2005-02       Impact factor: 3.982

7.  The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma.

Authors:  Adam C Berger; James C Watson; Eric A Ross; John P Hoffman
Journal:  Am Surg       Date:  2004-03       Impact factor: 0.688

  7 in total
  1 in total

Review 1.  Gene therapy in pancreatic cancer.

Authors:  Si-Xue Liu; Zhong-Sheng Xia; Ying-Qiang Zhong
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.